Zhongguancun announced that its subsidiary company Beijing Huasu Allolol Hydrochloride tablets application was accepted by the State Drug Administration. This drug is an alpha-beta blocker suitable for treating essential hypertension, angina pectoris, tachycardia arrhythmia, and primary tremors. Currently, 3 domestic generic drugs have been approved for marketing. In addition to Beijing Huasu, 4 domestic companies have submitted marketing license applications and are currently under review. The Allolol hydrochloride tablet project has invested a total of 6.09 million yuan in R&D expenses. If approved successfully, it will have a positive impact on the company's operating performance.

Zhitongcaijing · 07/02/2025 07:49
Zhongguancun announced that its subsidiary company Beijing Huasu Allolol Hydrochloride tablets application was accepted by the State Drug Administration. This drug is an alpha-beta blocker suitable for treating essential hypertension, angina pectoris, tachycardia arrhythmia, and primary tremors. Currently, 3 domestic generic drugs have been approved for marketing. In addition to Beijing Huasu, 4 domestic companies have submitted marketing license applications and are currently under review. The Allolol hydrochloride tablet project has invested a total of 6.09 million yuan in R&D expenses. If approved successfully, it will have a positive impact on the company's operating performance.